The supply of EpiPen® Jr 150mcg adrenaline (epinephrine) autoinjectors to Australia has been affected due to manufacturing delays from the manufacturer in the US, Meridian Medical Technologies, a Pfizer company. This means that there is currently a shortage of EpiPen® Jr as noted on the TGA website https://apps.tga.gov.au/prod/MSI/search and normal supply is expected by 31^st January 2020. 

Mylan, the supplier of EpiPen® Jr and EpiPen®  in Australia, will continue to provide updates about the supply situation and their latest update for consumers can be viewed here 
(Consumer notification EpiPen Jr supply constraint Nov 201991.10 KB).

Please note that supply of EpiPen® 300mcg adrenaline (epinephrine) autoinjectors is NOT affected.

Mylan has set up the following process to ensure those at risk for a potentially life-threatening allergic reaction (anaphylaxis) have access to the emergency treatment they may need:

• Patients requiring an EpiPen® Jr are being directed to contact their local pharmacy.

• Pharmacies can then contact the Mylan Customer Support team on 1800 274 276 or the EpiPen® Customer Service Toll Free hotline on 1800 931 625 or au.sales.support@mylan.com  to obtain instructions on how to access emergency supply.

See ASCIA information on use of an expired EpiPen®
www.allergy.org.au/about-ascia/info-updates/epipen-jr-supply-update

AND

www.allergy.org.au/hp/anaphylaxis/adrenaline-autoinjector-storage-expiry-and-disposal